Share or Print this page

Korean ADNI (K-ADNI) is working to comply with international standards of World Wide ADNI for development of new drugs for Alzheimer's disease dementia patients; to evaluate the effects of vascular risk factors on Alzheimer's disease progression and Subcortical Vascular Dementia (SVaD), which comprises a relatively large proportion of Asian dementia patients; and to establish the efficacy approval system for new dementia drugs.

After the setting up of infrastructure of multi-site data collection, they are currently trying to procure long-term public/private funding to collect data comparable to that gathered through other WW-ADNI centers and to be shared with the WW-ADNI community.

View more information about Korean ADNI.